501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro

• Main Authors: Haolin Liu (Author), Pengcheng Wei (Author), Qianqian Zhang (Author), Zhongzhou Chen (Author), Katja Aviszus (Author), Walter Downing (Author), Shelley Peterson (Author), Lyndon Reynoso (Author), Gregory P. Downey (Author), Stephen K. Frankel (Author), John Kappler (Author), Philippa Marrack (Author), Gongyi Zhang (Author)
• Format: Book
• Published: Taylor & Francis Group, 2021-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The newly emerging variants of SARS-CoV-2 from South Africa (B.1.351/501Y.V2) and Brazil (P.1/501Y.V3) have led to a higher infection rate and reinfection of COVID-19 patients. We found that the mutations K417N, E484K, and N501Y within the receptor-binding domains (RBDs) of the virus could confer ~2...